• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与西地那非口腔崩解膜相比,新型西地那非口服混悬液制剂的有效性及患者满意度:一项真实世界研究。

Effectiveness and patient satisfaction with the new sildenafil oral suspension formulation compared to sildenafil oro-dispersible film: a real-life study.

作者信息

Boeri Luca, Graps Giorgio, Zino Ester, Zago Agnese, Li Puma Andrea, Ciamarra Fabio, Cimmino Antonio, Parolin Valentina, Piccoli Michela, Gadda Franco, Montanari Emanuele, Albo Giancarlo

机构信息

Department of Urology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

出版信息

Int J Impot Res. 2025 Jan 29. doi: 10.1038/s41443-025-01019-4.

DOI:10.1038/s41443-025-01019-4
PMID:39881012
Abstract

Sildenafil is one of the most used phosphodiesterase type 5 inhibitor (PDE5i) for the treatment of erectile dysfunction (ED) in clinical practice. A new oral suspension formulation (OSF) of sildenafil has been introduced to overcome the drawbacks of previous formulations. We assess the efficacy and patients' experience with sildenafil 50 mg OSF in men with ED who were taking the sildenafil oro-dispersible film (ODF). Demographics and clinical data from 70 consecutive men with mild-moderate ED were analysed. Patients were treated with sildenafil 50 mg ODF for 12 weeks (follow-up 1), then, after 2-week washout, were administered sildenafil 50 mg OSF for 12 weeks (follow-up 2). At each follow-up, patients completed the International Index of Erectile Function (IIEF), the Patient Global Impression of Improvement (PGI-I), and the Psychological and Interpersonal Relationship Scales-Short Form (PAIRS-SF) questionnaires. Descriptive statistics described the whole cohort. The Wilcoxon Signed Rank Test assessed potential differences in psychometric scores at different follow-up assessments. Logistic regression analyses tested the associations between study variables and satisfaction after sildenafil OSF treatment. Overall, median age was 56 (51-62) years, and median IIEF-EF score was 14 (12-17). Compared to baseline, IIEF-EF scores significantly improved after sildenafil ODF and OSF treatment (all p < 0.01) with no differences between the two formulations. IIEF-overall satisfaction (OS) was higher after sildenafil OSF than ODF (p < 0.001). Similarly, median PGI-I score were better after sildenafil OSF than ODF (p < 0.001). The PAIRS-SF spontaneity scores were significantly higher after OSF than ODF (p < 0.01). At multivariable logistic regression analysis, younger age (p = 0.02) and lower baseline IIEF-EF scores (p = 0.01) were independent predictors of improved satisfaction with OSF compared to ODF. The sildenafil OSF and ODF had similar efficacy, however the new OSF provides higher satisfaction and spontaneity scores compared to the oro-dispersible film.

摘要

西地那非是临床实践中治疗勃起功能障碍(ED)最常用的5型磷酸二酯酶抑制剂(PDE5i)之一。一种新的西地那非口服混悬剂配方(OSF)已被引入,以克服先前配方的缺点。我们评估了50毫克西地那非OSF对正在服用西地那非口腔崩解膜(ODF)的ED男性患者的疗效和患者体验。分析了70例连续的轻度至中度ED男性的人口统计学和临床数据。患者先服用50毫克西地那非ODF治疗12周(随访1),然后在2周洗脱期后,服用50毫克西地那非OSF治疗12周(随访2)。在每次随访时,患者完成国际勃起功能指数(IIEF)、患者总体改善印象(PGI-I)以及心理和人际关系量表简表(PAIRS-SF)问卷。描述性统计描述了整个队列。Wilcoxon符号秩检验评估了不同随访评估中心理测量分数的潜在差异。逻辑回归分析测试了研究变量与西地那非OSF治疗后满意度之间的关联。总体而言,中位年龄为56(51 - 62)岁,中位IIEF-EF评分为14(12 - 17)。与基线相比,西地那非ODF和OSF治疗后IIEF-EF评分均显著改善(所有p < 0.01),两种配方之间无差异。西地那非OSF治疗后的IIEF总体满意度(OS)高于ODF(p < 0.001)。同样,西地那非OSF治疗后的中位PGI-I评分优于ODF(p < 0.001)。OSF治疗后的PAIRS-SF自发性评分显著高于ODF(p < 0.01)。在多变量逻辑回归分析中,与ODF相比,年龄较小(p = 0.02)和基线IIEF-EF评分较低(p = )是对OSF满意度提高的独立预测因素。西地那非OSF和ODF疗效相似,然而与口腔崩解膜相比,新的OSF提供了更高的满意度和自发性评分。 (注:原文中一处“基线IIEF-EF评分较低(p = )”括号内p值缺失,翻译时保留原文格式)

相似文献

1
Effectiveness and patient satisfaction with the new sildenafil oral suspension formulation compared to sildenafil oro-dispersible film: a real-life study.与西地那非口腔崩解膜相比,新型西地那非口服混悬液制剂的有效性及患者满意度:一项真实世界研究。
Int J Impot Res. 2025 Jan 29. doi: 10.1038/s41443-025-01019-4.
2
Effectiveness and Safety of Oro-Dispersible Sildenafil in a New Film Formulation for the Treatment of Erectile Dysfunction: Comparison Between Sildenafil 100-mg Film-Coated Tablet and 75-mg Oro-Dispersible Film.新型口崩型薄膜制剂的西地那非治疗勃起功能障碍的有效性和安全性:100 毫克薄膜包衣片剂与 75 毫克口崩型薄膜的比较。
J Sex Med. 2017 Dec;14(12):1606-1611. doi: 10.1016/j.jsxm.2017.10.066. Epub 2017 Nov 16.
3
Bedtime sildenafil oral suspension improves sexual spontaneity and time-concerns compared to on-demand treatment in men with erectile dysfunction: results from a real-life, cross-sectional study.与按需治疗相比,睡前服用西地那非口服混悬液可改善勃起功能障碍男性的性自发性和时间顾虑:一项真实生活横断面研究的结果
Int J Impot Res. 2025 Feb 24. doi: 10.1038/s41443-025-01035-4.
4
Effect of the new 75-mg orodispersible film of sildenafil on erection and sexual quality of life: insights from an observational study.新型75毫克西地那非口腔崩解膜对勃起功能及性生活质量的影响:一项观察性研究的见解
Sex Med. 2023 Mar 1;11(2):qfac007. doi: 10.1093/sexmed/qfac007. eCollection 2023 Apr.
5
Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors.西地那非口腔崩解膜的舌下给药:PDE5抑制剂药物耐受性和药代动力学的新概况。
Front Pharmacol. 2018 Feb 6;9:59. doi: 10.3389/fphar.2018.00059. eCollection 2018.
6
Next-generation pharmaceuticals: the rise of sildenafil citrate ODF for the treatment of men with erectile dysfunction.下一代药物:枸橼酸西地那非口腔崩解片用于治疗男性勃起功能障碍的兴起。
Ther Deliv. 2025 Apr;16(4):365-378. doi: 10.1080/20415990.2024.2445501. Epub 2025 Jan 12.
7
Assessment of a New Formulation of Sildenafil on Common Practice: An Observational Study.西地那非新剂型在常规实践中的评估:一项观察性研究。
Int J Reprod Med. 2022 Jun 2;2022:9122099. doi: 10.1155/2022/9122099. eCollection 2022.
8
Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.首次接受磷酸二酯酶5抑制剂治疗的男性中,与选择西地那非和他达拉非治疗勃起功能障碍相关的因素:一项多中心、随机、开放标签、交叉研究数据的事后分析
BJU Int. 2007 Jul;100(1):122-9. doi: 10.1111/j.1464-410X.2007.06916.x.
9
Efficacy and Safety of Mirodenafil Oro-Dispersible Film in Korean Patients with Erectile Dysfunction: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Phase IV Study.米罗地那非口腔崩解片在韩国勃起功能障碍患者中的疗效与安全性:一项双盲、随机、安慰剂对照、平行组、多中心、IV期研究。
World J Mens Health. 2022 Apr;40(2):280-289. doi: 10.5534/wjmh.200157. Epub 2021 Jan 21.
10
Predictors of Erectile Function Normalization in Men With Erectile Dysfunction Treated With Placebo.治疗勃起功能障碍的安慰剂对男性勃起功能正常化的预测因素。
J Sex Med. 2018 Jun;15(6):866-872. doi: 10.1016/j.jsxm.2018.03.089. Epub 2018 May 9.

本文引用的文献

1
Treatment preferences of patients with erectile dysfunction: a systematic review of randomized controlled trials.勃起功能障碍患者的治疗偏好:一项随机对照试验的系统评价。
Minerva Urol Nephrol. 2024 Feb;76(1):42-51. doi: 10.23736/S2724-6051.23.05552-0.
2
Study UNICO: Perception of Urologists and Andrologists, in Spain, about the Use of Sildenafil Oral Suspension in Patients with Erectile Dysfunction.研究 UNICO:西班牙泌尿科医师和男科医师对口服西地那非混悬液治疗勃起功能障碍患者的认知。
Arch Esp Urol. 2023 Mar;76(2):139-144. doi: 10.56434/j.arch.esp.urol.20237602.15.
3
Primary organic versus primary psychogenic erectile dysfunction: Findings from a real-life cross-sectional study.
原发性器质性与原发性心因性勃起功能障碍:来自真实横断面研究的发现。
Andrology. 2022 Oct;10(7):1302-1309. doi: 10.1111/andr.13212. Epub 2022 Jun 30.
4
European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction.欧洲泌尿外科学会 2021 年性与生殖健康指南更新:男性性功能障碍。
Eur Urol. 2021 Sep;80(3):333-357. doi: 10.1016/j.eururo.2021.06.007. Epub 2021 Jun 26.
5
Practical Approaches to Treat ED in PDE5i Nonresponders.治疗对5型磷酸二酯酶抑制剂无反应的勃起功能障碍的实用方法。
Aging Dis. 2020 Oct 1;11(5):1202-1218. doi: 10.14336/AD.2019.1028. eCollection 2020 Oct.
6
Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.口服磷酸二酯酶 5 抑制剂治疗勃起功能障碍的疗效和安全性:一项网状 meta 分析和多准则决策分析。
World J Urol. 2021 Mar;39(3):953-962. doi: 10.1007/s00345-020-03233-9. Epub 2020 May 9.
7
Longitudinal Risk of Developing Cardiovascular Diseases in Patients With Erectile Dysfunction-Which Patients Deserve More Attention?勃起功能障碍患者发生心血管疾病的纵向风险——哪些患者更值得关注?
J Sex Med. 2020 Aug;17(8):1489-1494. doi: 10.1016/j.jsxm.2020.03.012. Epub 2020 Apr 24.
8
Degree of Planning of Sexual Intercourse Among Men From China, Japan, and Taiwan Taking Medication for Erectile Dysfunction: Findings of an Observational, Cross-Sectional Survey.来自中国、日本和台湾地区正在服用勃起功能障碍药物的男性的性交计划程度:一项观察性横断面调查的结果
Sex Med. 2019 Mar;7(1):54-60. doi: 10.1016/j.esxm.2018.10.006. Epub 2018 Dec 3.
9
Clinical Profile of Young Patients with Erectile Dysfunction: Preliminary Findings of a Real-life Cross-sectional Study.年轻勃起功能障碍患者的临床特征:一项真实世界横断面研究的初步发现。
Eur Urol Focus. 2020 Jan 15;6(1):184-189. doi: 10.1016/j.euf.2018.10.003. Epub 2018 Oct 11.
10
Does Calculated Free Testosterone Overcome Total Testosterone in Protecting From Sexual Symptom Impairment? Findings of a Cross-Sectional Study.计算游离睾酮能否克服总睾酮在保护性功能障碍方面的作用?一项横断面研究的结果。
J Sex Med. 2017 Dec;14(12):1549-1557. doi: 10.1016/j.jsxm.2017.10.070.